All Stories

  1. The impact of disease extent and severity detected by quantitative ultrasound analysis in the diagnosis and outcome of giant cell arteritis

    Article • Rheumatology, December 2019, Oxford University Press (OUP)

    Sara Monti

  2. Systematic literature review informing the 2018 update of the EULAR recommendation for the management of large vessel vasculitis: focus on giant cell arteritis

    Article • RMD Open, September 2019, BMJ

    Sara Monti

  3. Management of Takayasu arteritis: a systematic literature review informing the 2018 update of the EULAR recommendation for the management of large vessel vasculitis

    Article • RMD Open, September 2019, BMJ

    Sara Monti

  4. 2018 Update of the EULAR recommendations for the management of large vessel vasculitis

    Article • Annals of the Rheumatic Diseases, July 2019, BMJ

    Sara Monti

  5. THU0290 DISEASE AND TREATMENT-RELATED MORBIDITY IN YOUNG AND ELDERLY PATIENTS WITH ANCA-ASSOCIATED VASCULITIS

    Article • June 2019, BMJ

    Sara Monti

  6. FRI0287 EFFICACY OF EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS TREATMENTS ACCORDING TO THE TYPE OF MANIFESTATIONS BASED ON ANALYSIS OF 636 PATIENTS

    Article • June 2019, BMJ

    Sara Monti

  7. THU0286 MANAGEMENT OF TAKAYASU ARTERITIS: A SYSTEMATIC LITERATURE REVIEW INFORMING THE 2018 UPDATE OF THE EULAR RECOMMENDATIONS FOR THE MANAGEMENT OF LARGE VESSEL VASCULITIS

    Article • June 2019, BMJ

    Sara Monti

  8. SAT0239 PREDICTION OF LONG-TERM EVOLUTIONARY PROFILES IN EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS (CHURG–STRAUSS) BASED ON BASELINE AND FOLLOW-UP CHARACTERISTICS

    Article • June 2019, BMJ

    Sara Monti

  9. FRI0284 RESULTS OF A SYSTEMATIC LITERATURE REVIEW INFORMING THE 2018 UPDATE OF THE EULAR RECOMMENDATIONS FOR THE MANAGEMENT OF LARGE VESSEL VASCULITIS: EVIDENCE TO GUIDE THE MANAGEMENT OF GIANT CELL ARTERITIS

    Article • June 2019, BMJ

    Sara Monti

  10. IgG4-related diseases: state of the art on clinical practice guidelines

    Article • RMD Open, January 2019, BMJ

    Sara Monti

  11. Aging in Primary Systemic Vasculitis: Implications for Diagnosis, Clinical Manifestations, and Management

    Article • Drugs & Aging, November 2018, Springer Science + Business Media

    Sara Monti

  12. 20 years of experience with tumour necrosis factor inhibitors: what have we learned?

    Article • Rheumatology, October 2018, Oxford University Press (OUP)

    Sara Monti

  13. Randomized controlled trials and real-world data: differences and similarities to untangle literature data

    Article • Rheumatology, October 2018, Oxford University Press (OUP)

    Sara Monti

  14. The role of extra-corporeal membrane oxygenation (ECMO) in the treatment of diffuse alveolar haemorrhage secondary to ANCA-associated vasculitis: report of two cases and review of the literature

    Article • Rheumatology International, August 2018, Springer Science + Business Media

    Sara Monti

  15. OP0238 Association between age at diagnosis and clinical presentation and outcomes of anca-associated vasculitis. analysis from the dcvas study

    Article • June 2018, BMJ

    Sara Monti

  16. SAT0327 Baseline characteristics and reasons for apremilast prescription in a large italian cohort of psoriatic arthritis patients

    Article • June 2018, BMJ

    Sara Monti

  17. FRI0504 Diffuse alveolar haemorrhagein anca-associated vasculitis: can we predict outcome? an italian multicentre retrospective long-term study of 102 patients

    Article • June 2018, BMJ

    Sara Monti

  18. FRI0114 Efficacy and retention rate of certolizumab pegol in rheumatoid arthritis: data from a large real-life multicentre retrospective cohort

    Article • June 2018, BMJ

    Sara Monti

  19. AB0700 Is it feasible to withdraw immunosuppressive treatment in real-life patients with anca-associated vasculitis?

    Article • June 2018, BMJ

    Sara Monti

  20. OP0333 Survival in anca associated vasculitides: a retrospective multicentric analysis in northern italy

    Article • June 2018, BMJ

    Sara Monti

  21. Clinical spectrum of anti-Jo-1-associated disease

    Article • Current Opinion in Rheumatology, November 2017, Wolters Kluwer Health

    Sara Monti

  22. The proposed role of ultrasound in the management of giant cell arteritis in routine clinical practice

    Article • Rheumatology, October 2017, Oxford University Press (OUP)

    Sara Monti

  23. How I treat idiopathic patients with inflammatory myopathies in the clinical practice

    Article • Autoimmunity Reviews, October 2017, Elsevier

    Sara Monti

  24. Prevalence of Ankylosing Spondylitis Disease Activity Score (ASDAS) inactive disease in a cohort of patients treated with TNF-alpha inhibitors

    Article • Modern Rheumatology, September 2017, Taylor & Francis

    Sara Monti

  25. THU0297 A novel ultrasound scoring system for giant cell arteritis

    Article • June 2017, BMJ

    Sara Monti

  26. FRI0337 Anca pattern in granulomatosis with polyangitis and micropolyangitis. a retrospective analysis on a multicentric inception cohort

    Article • June 2017, BMJ

    Sara Monti

  27. THU0302 Histology findings in giant cell arteritis (GCA) and their relationship with the ultrasound results: analysis of data from the tabul study (temporal artery biopsy vs ultrasound in diagnosis of giant cell arteritis)

    Article • June 2017, BMJ

    Sara Monti

  28. FRI0312 The frequency and severity of patient-reported symptoms in giant cell arteritis

    Article • June 2017, BMJ

    Sara Monti

  29. AB0589 The role of anca specificity in the clinical manifestations at disease onset: comparison between patients with granulomatosis with polyangiitis and microscopic polyangiitis

    Article • June 2017, BMJ

    Sara Monti

  30. THU0296 The role of ultrasound in the management of giant cell arteritis (GCA) in routine clinical practice

    Article • June 2017, BMJ

    Sara Monti

  31. ANCA-associated vasculitis in childhood: recent advances

    Article • Italian Journal of Pediatrics, May 2017, Springer Science + Business Media

    Sara Monti

  32. The use of ultrasound to assess giant cell arteritis: review of the current evidence and practical guide for the rheumatologist

    Article • Rheumatology, April 2017, Oxford University Press (OUP)

    Sara Monti

  33. Factors influencing the choice of first- and second-line biologic therapy for the treatment of rheumatoid arthritis: real-life data from the Italian LORHEN Registry

    Article • Clinical Rheumatology, January 2017, Springer Science + Business Media

    Sara Monti

  34. AB0569 Does The Age at Disease Onset Influence The Clinical Presentation and Long-Term Outcome of Anca-Associated Vasculitides? Results from A Single-Centre Cohort: Table 1.

    Article • Annals of the Rheumatic Diseases, June 2016, BMJ

    Sara Monti

  35. FRI0232 Factors Influencing The Choice of First and Second Line Biologic Therapy for The Treatment of Rheumatoid Arthritis: Real Life Data from The Italian Lorhen Registry

    Article • Annals of the Rheumatic Diseases, June 2016, BMJ

    Sara Monti

  36. AB0226 One Year Experience of A Bdmard Spacing Protocol in Real Life Rheumatoid Arthritis Patients

    Article • Annals of the Rheumatic Diseases, June 2016, BMJ

    Sara Monti

  37. FRI0174 Two-Year Retention Rate of Subcutaneous Anti-Tumor Necrosis Factor Agents for Rheumatoid Arthritis: A Retrospective Analysis of The Lorhen Registry

    Article • Annals of the Rheumatic Diseases, June 2016, BMJ

    Sara Monti

  38. Chronic pain: the burden of disease and treatment innovations

    Article • Reumatismo, October 2015, PAGEPress Publications

    Sara Monti

  39. Switching from Intravenous to Subcutaneous Formulation of Abatacept: Different Results in a Series of 21 Patients

    Article • The Journal of Rheumatology, October 2015, The Journal of Rheumatology

    Sara Monti

  40. Rheumatoid arthritis treatment: the earlier the better to prevent joint damage

    Article • RMD Open, August 2015, BMJ

    Sara Monti

  41. AB0401 Anxiety and Depression in Patients with Rheumatoid Arthritis Treated with Biological Drugs: Prevalence and Relationship with Disease Activity

    Article • Annals of the Rheumatic Diseases, June 2015, BMJ

    Sara Monti

  42. AB0426 Biologic Spacing in Rheumatoid Arthritis Patients in Persistent Disease Activity Control: A Real Life Experience

    Article • Annals of the Rheumatic Diseases, June 2015, BMJ

    Sara Monti

  43. FRI0182 Comorbidities Influence the Choice of the Biologic Agent: Real Life Data from the Lorhen Registry

    Article • Annals of the Rheumatic Diseases, June 2015, BMJ

    Sara Monti

  44. FRI0278 Life-Threatening Onset of Systemic Vasculitis Requiring Intensive Care Unit Admission: A Case Series

    Article • Annals of the Rheumatic Diseases, June 2015, BMJ

    Sara Monti

  45. AB0664 Off Label Biologic Therapy in a Cohort of Patients with Behçet Disease

    Article • Annals of the Rheumatic Diseases, June 2015, BMJ

    Sara Monti

  46. AB0788 Treating Axial-Spa to Target: Prevalence of Ankylosing Spondylitis Disease Activity Score (ASDAS) Inactive Disease in a Cohort of Patients Treated with Anti-TNFα Agents

    Article • Annals of the Rheumatic Diseases, June 2015, BMJ

    Sara Monti

  47. Risk of hepatitis B virus reactivation in rheumatoid arthritis patients undergoing biologic treatment: Extending perspective from old to newer drugs

    Article • World Journal of Hepatology, January 2015, Baishideng Publishing Group Co., Limited (formerly WJG Press)

    Sara Monti

  48. Perivascular fibrosis and IgG4-related disease: a case report

    Article • Reumatismo, November 2014, PAGEPress Publications

    Sara Monti

  49. Pneumocephalus due to granulomatosis with polyangiitis

    Article • Rheumatology, September 2014, Oxford University Press (OUP)

    Sara Monti

  50. Circulating suPAR levels are affected by glomerular filtration rate and proteinuria in primary and secondary glomerulonephritis

    Article • Journal of Nephrology, September 2014, Springer Science + Business Media

    Sara Monti

  51. Osteopontin circulating levels correlate with renal involvement in systemic lupus erythematosus and are lower in ACE inhibitor-treated patients

    Article • Clinical Rheumatology, May 2014, Springer Science + Business Media

    Marco Quaglia, Sara Monti

  52. Spinal non-Hodgkin’s lymphoma mimicking a flare of disease in a patient with ankylosing spondylitis treated with anti-TNF agents: case report and review of the literature

    Article • Clinical Rheumatology, April 2014, Springer Science + Business Media

    Sara Monti

  53. The Multifaceted Aspects of Interstitial Lung Disease in Rheumatoid Arthritis

    Article • BioMed Research International, January 2013, Hindawi Publishing Corporation

    Sara Monti